PROTXX and University of Alberta Announce Remote Personalized Healthcare Management of Patients With Multiple Sclerosis

PROTXX | July 01, 2020

Silicon Valley, California and Calgary, Alberta based precision medicine technology pioneer PROTXX and the University of Alberta in Edmonton, Alberta today announced a new research collaboration that will leverage the PROTXX precision healthcare platform for remote personalized health management of patients with multiple sclerosis (MS). The PROTXX precision healthcare platform integrates wearable sensor and machine learning innovations to replace bulky and expensive clinical equipment and time-consuming testing procedures for a variety of neurodegenerative medical conditions in which patients suffer from impairments to multiple physiological systems. PROTXX solves the difficult problem of identifying and quantifying these multiple different impairments, disrupting diagnosis and treatment with easy-to-use, low-cost, precision patient assessments. MS is an autoimmune inflammatory and neurodegenerative disease of the central nervous system (CNS) that causes progressive disability in motor, visual, sensory, autonomic, and cognitive functions. The prevalence of MS in Canada is among the highest reported in the world, affecting over 100,000 Canadians and costing the Canadian healthcare system close to one billion dollars per year. Moreover, MS is on the rise in Canada, predominantly amongst women, and is the leading cause of neurological disability amongst people ages 20-40 years. MS has been dubbed "Canada's disease" by Maclean's (April 27, 2015). The University of Alberta and PROTXX have been awarded a Mitacs Accelerate grant to support post-doctoral research fellows participating in the project in 2020-2021. Project co-leads at the University of Alberta are:

Spotlight

Consumer-Driven Health Plans (CDHP) can be an effective way of reducing total medical cost. However, few have studied differences in the customer experience attributable to plan type (HRA or HSA) within the CDHP universe of offerings.


Other News
HEALTH TECHNOLOGY

Viemed Announces Publication of Peer-Reviewed NIVH Study Finding Treatment Reduces Healthcare Costs and Saves Lives

Viemed Healthcare, Inc. | July 06, 2022

Viemed Healthcare, Inc. a national leader in respiratory care and technology-enabled home medical equipment services, announced a third peer-reviewed and published study demonstrating the benefits of non-invasive ventilation at home The study, titled “Early Initiation of Non-Invasive Ventilation at Home Improves Survival and Reduces Healthcare Costs in COPD Patients with Chronic Hypercapnic Respiratory Failure: A Retrospective Cohort Study” was published in Respiratory Medicine, an internationally renowned scientific journal devoted to respiratory medical research. “In addition to the significant clinical benefits demonstrated in previously published papers, this study demonstrates that NIVH improves health outcomes while simultaneously driving down overall healthcare costs. The study was also designed to investigate how the timing of NIVH initiation affected the outcomes. The results showed that the clinical and financial benefits of NIVH are greatest when therapy begins immediately following the diagnosis.” Dr. William Frazier, Viemed’s Chief Medical Officer and co-author of the study Using the 100% research identifiable fee-for-service Medicare claims from 2016 through 2020, the researchers found that using NIVH to treat chronic obstructive pulmonary disease with chronic hypercapnic respiratory failure is associated with significant reductions in mortality, hospitalizations, and total Medicare costs. In terms of cost-savings, Medicare expenditures for the year following NIVH initiation decreased by $5,484 compared to controls if treatment was begun within seven days of diagnosis. The cost reduction was $3,412 if NIVH was begun within 15 days of diagnosis. For patients whose therapy began more than 15 days after diagnosis, NIVH use was cost neutral and not associated with an increase in Medicare expenditures. The primary clinical benefit was a reduced mortality in patients treated with NIVH. When a patient began therapy within seven days of diagnosis, the risk of death was reduced by 43%. Those patients who began therapy between eight and 15 days following diagnosis showed a mortality reduction of 31%, and patients who began therapy between 16 and 30 days following diagnosis showed a mortality reduction of 16%. “NIVH is becoming widely accepted by clinicians as the standard of care for hypercapnic COPD-CRF treatment and this evidence supporting early initiation will help us to communicate the clinical and economic benefits to payors and partners,” said Casey Hoyt, Viemed’s CEO. “By accessing and treating more patients sooner, we can save lives, reduce hospital readmissions, and save money at the same time.” ABOUT VIEMED HEALTHCARE, INC. Viemed is a provider of in-home medical equipment and post-acute respiratory healthcare services in the United States. Viemed’s service offerings are focused on effective in-home treatment with clinical practitioners providing therapy and counseling to patients in their homes using cutting edge technology.

Read More

HEALTH TECHNOLOGY

Valtruis Brings Advanced Healthcare Data Analytics Capabilities Into Its Portfolio With Ursa Health Partnership

Ursa Health and Valtruis | June 28, 2022

Valtruis, a WCAS company, has entered a strategic partnership with Ursa Health, a healthcare data analytics company that brings a paradigm-breaking approach to how healthcare organizations use their data to learn, make decisions, and innovate Valtruis portfolio companies Cricket Health and Wayspring are already experiencing quantifiable advances in their data analysis and management capabilities through both the Ursa Studio no-code analytics development platform and the unusually productive training, support, and consultative relationships they have formed with Ursa Health’s team of healthcare IT and data analytics experts. “Building on the investments made in our first year – with Cricket Health, Wayspring, U.S. Medical Management (USMM) and Oncology Care Partners – we are moving quickly and strategically to realize our foundational commitment,” said Valtruis Managing Director Karey Witty. “That commitment is to accelerate the adoption of value-based care through investments in and collaboration with companies and entrepreneurs that share the vision, talent, and innovative strategies to make value-based care a reality. Ursa Health is one of those companies.” “We bring scalable innovation to healthcare. Companies driving toward meaningful strategic innovation need their data to provide richer, more nuanced answers than healthcare as an industry has historically delivered – and they need these insights at the speed of business. Ursa Studio is a technology that unlocks a fresh approach to developing trusted information. On the technical level, the platform shifts IT team time from the labor of debugging code and managing data plumbing, opening up their capacity to answer additional business questions. On the human level, the platform enables rapid iteration and collaboration between the producers and consumers of analytics, bringing teams to a successful endpoint more quickly. As a result, organizations gain the self-service capacity to fill their information gaps and guide their innovations more efficiently and effectively.” Ursa Health CEO and Co-Founder Robin Clarke, MD Early-phase successes from Valtruis’ partner companies attest to the value, intelligence, and flexibility of the Ursa Health technology and analytics approach. Adam Dunning, Chief Information and Analytics Officer at Wayspring, stated: “We needed a solution to fast-track the development of our SUD Home offering. Working with Ursa Studio, allowed us to accelerate the building of foundational data analytics structures. Our clients and staff will see notable returns as we continue to master the technology offering developed by Ursa Health.” About Valtruis Valtruis, a WCAS company, provides a unique platform that invests in and partners with disruptive leaders whose mission is to align, and transform healthcare through what is truly value-based care. Founded on a commitment to accelerate meaningful change, Valtruis brings the functional expertise, access to capital, and an expansive network that advance our partners’ evolution from early-stage development to industry-leading enterprises. Together, Valtruis and its partner companies will break through the systemic barriers in the healthcare industry to reduce costs, expand access, increase quality, and radically improve the patient experience. About Ursa Health Ursa Health is transforming analytics so innovators can transform healthcare. Our analytics development platform, Ursa Studio, combines no-code technology with healthcare-specific content, enabling health plans, providers, digital health companies, and others to take a Buy Your Build™ approach to their analytics infrastructure. With the structured adaptability of Ursa Studio, organizations can make full use of their rich data resources to accelerate growth.

Read More

HEALTH TECHNOLOGY

athenahealth Expands Mobile EHR Voice Capabilities for Healthcare Providers

athenahealth, Inc. | June 29, 2022

athenahealth, Inc., a leading provider of network-enabled software and services for medical groups and health systems nationwide, announced the release of athenaOne® Voice Assistant Powered by Nuance®, a mobile-embedded, voice-driven digital companion that streamlines information retrieval and enables hands-free completion of meaningful clinical tasks for healthcare providers using athenahealth’s electronic health records (EHR) solution. Leveraging the power of their voice and iOS-based mobile device, clinicians can spend less time on the computer and more time interacting with patients. Voice Assistant is a natural command-based, virtual assistant developed and built by athenahealth and powered by Nuance's Dragon Medical technology. Voice Assistant is available for use with the award-winning athenaOne mobile app and athenaOne® Dictation Powered by Nuance®, which allows clinicians to dictate patient documentation naturally and accurately. Together, athenahealth’s voice-enabled solutions help clinicians improve documentation accuracy, save time, and provide a better patient experience. According to a recent survey by athenahealth, 92% of physicians surveyed report one or more issues cause them to feel burned out on a regular basis with the leading cause of regular burnout being excessive documentation requirements. However, numerous clinicians using Voice Assistant have experienced significant documentation time savings, thus allowing them to reallocate their time to other high-priority tasks. “I started using Voice Assistant because I’m curious about tech and AI, and I wanted to see if it would help me be more productive. Because I can so easily document anywhere, anytime, I’ve found it to be very useful and convenient, and it helps me make better use of my time. I wouldn’t want to work without it now.” Dr. Terence M. Grogan, DO, FAAFP, Grogan Family Medicine Using simple, intuitive voice commands, clinicians using Voice Assistant can document exams, create draft orders, retrieve clinical information, and review their schedule to accelerate tasks and save valuable time. As an AI-backed technology, Voice Assistant will become even smarter and more efficient with widespread use, and athenahealth will continue to expand the number of available commands and introduce new use cases. “We are delighted to expand our provider mobile app capabilities with Voice Assistant as we continue to transform the provider and patient experience,” said Paul Brient, chief product officer for athenahealth. “Clinicians should be able to experience technology at work just like they do in their everyday lives, and Voice Assistant brings us one step closer to that.” Brient added that with provider burnout and patient expectations increasing simultaneously, athenahealth is focused on accelerating product innovation, using tools like AI to help solve some of healthcare's biggest challenges. “As our data show, administrative requirements are taking too much time and attention away from providers, and it’s the responsibility of all EHR companies to decrease that burden so providers can spend more face time with patients,” he said. About athenahealth, Inc. athenahealth creates innovative healthcare technology that connects clinicians, patients, payers, and partners in differentiated ways. Our electronic health records, revenue cycle management, and patient engagement tools allow anytime, anywhere access, driving better financial outcomes for our customers and enabling our provider customers to deliver better quality care. In everything we do, we’re inspired by our vision to create a thriving ecosystem that delivers accessible, high-quality, and sustainable healthcare for all.

Read More

FUTURE OF HEALTHCARE

Concord Health Partners Adds Healthcare Veteran Brian Gragnolati as Executive Partner

Concord Health Partners | July 12, 2022

Concord Health Partners a healthcare focused investment firm, announced that Brian Gragnolati has joined as Executive Partner. Gragnolati currently serves as President and CEO of Atlantic Health System. During his tenure at Atlantic Health System, he also served as Chairman of the Board of Trustees of the American Hospital Association. The addition of Gragnolati as Executive Partner further expands Concord's team of healthcare sector specialists, adding the network, knowledge and insights of an experienced CEO and a nationally recognized leader in the provider industry. Gragnolati will work with James Olsen, Founder and Managing Partner, and other members of the Concord team to source new investment opportunities, support management teams and accelerate the growth of portfolio companies through commercial introductions across the Concord network of strategic relationships. "We are thrilled to add someone with Brian's experience, knowledge and expertise to Concord's executive team. We established Concord with the goal of creating lasting partnerships with strategic investors to help drive the adoption of our portfolio company technologies and solutions across a broad universe of healthcare providers and payors. Brian brings unique perspective from his roles as a health system chief executive officer and at the AHA, and has distinguished himself as a valuable partner to Concord in those roles. We look forward to leveraging his insights and network as he helps identify new opportunities and accelerate growth at our portfolio companies as Executive Partner." James Olsen, Founder and Managing Partner at Concord "In working with Concord over the years, it was clear that the Firm has developed a powerful model for healthcare investing. Concord has become a leader in identifying innovative companies and partnering with them to drive growth," said Gragnolati. "I am excited at the opportunity to work even more closely with the Concord team and their portfolio companies to help them continue to deliver solutions that lower costs, improve quality and expand access to care." Gragnolati has served as President and CEO of Atlantic Heath System since 2015, and is the former Chairman of the Board of Trustees of the AHA. Prior to his tenure at Atlantic Health, Brian served as Senior Vice President at Johns Hopkins Medicine. He previously held executive positions at Wellspan Health, University of Vermont Medical Center and Baystate Medical Center in Springfield, MA. As a nationally respected voice in health care, Mr. Gragnolati played a key role in public relations and media communications during the COVID pandemic. He regularly appears on CNBC, MSNBC, Bloomberg and other media outlets to share his insight on the nation's most pressing health concerns. He has been honored by Modern Healthcare as one of the 100 most influential people in healthcare. He serves on the Board of Directors of Lakeland Bancorp, Inc. and Lakeland Bank. Gragnolati holds a bachelor's degree in Health Systems Analysis from the University of Connecticut, an MBA from Western New England College and an Executive Leadership Certificate from the JFK School at Harvard University. About Concord Health Partners Concord Health Partners is a healthcare focused investment firm with a strategic model that optimizes the alignment of interests between investors and portfolio companies. Concord has developed a broad network of strategic investors that contribute expertise and resources, and serve as potential commercial partners to portfolio companies. Concord is primarily focused on investing in healthcare companies that have the potential to enhance the value of care through products, services, technologies and solutions that lower costs, improve quality and expand access to care.

Read More

Spotlight

Consumer-Driven Health Plans (CDHP) can be an effective way of reducing total medical cost. However, few have studied differences in the customer experience attributable to plan type (HRA or HSA) within the CDHP universe of offerings.

Resources